Indivior Pharmaceuticals (INDV) has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program, Indivior said Monday.
The company will make a $175 million upfront payment to Barclays and expects to receive an initial delivery of 3,717,473 shares following execution.
Indivior said it expects final settlement no later than the end of June.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.